RHAMM silencing abrogated the self-renewing property of glioblastoma stem cells, and loss of RHAMM in malignant peripheral nerve sheath tumors or multiple myeloma sensitizes tumor cells to inhibitors (394–396). This evidence concerns the gene HMMR and plasma cell myeloma.